domatinostat in combination with avelumab
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma
Trial Timeline
Nov 1, 2021 → Sep 1, 2025
NCT ID
NCT04874831About domatinostat in combination with avelumab
domatinostat in combination with avelumab is a phase 2 stage product being developed by Merck for Merkel Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04874831. Target conditions include Merkel Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04874831 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Merkel Cell Carcinoma